Journal Article

Origin, structure, and activity <i>in vitro</i> and <i>in vivo</i> of dalbavancin

Adriano Malabarba and Beth P. Goldstein

in Journal of Antimicrobial Chemotherapy

Volume 55, issue suppl_2, pages ii15-ii20
Published in print March 2005 | ISSN: 0305-7453
Published online March 2005 | e-ISSN: 1460-2091 | DOI:
Origin, structure, and activity in vitro and in vivo of dalbavancin

Show Summary Details


Dalbavancin is a novel semi-synthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin. Chemical modification of natural glycopeptides has produced compounds with more potent antimicrobial activity and longer t1/2, while maintaining an excellent safety profile. Dalbavancin, prepared from a teicoplanin-like glycopeptide, has better activity, in vitro and in animal infection models, than vancomycin and teicoplanin. In particular, dalbavancin has excellent activity against staphylococci, including coagulase-negatives. A unique feature of dalbavancin is its pharmacokinetics, characterized by a long elimination t1/2 in humans which makes a once-weekly dosing regimen feasible. Dalbavancin recently completed Phase 3 clinical trials in skin and skin structure infection.

Keywords: glycopeptides; structure–activity relationships; Gram-positive; staphylococci

Journal Article.  0 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.